BACKGROUND: Infiltration, accumulation, and degranulation of eosinophils in the lung are hallmarks of active allergic asthma. The pulmonary response to inhaled allergen triggers the secretion of eosinophil chemoattractants and antiapoptotic cytokines, including GM-CSF, IL-3, IL-4, IL-5, and eotaxin, among others. We recently showed that in vitro Pin1 regulated eosinophil production of and response to GM-CSF. OBJECTIVE: We sought to determine the effect of Pin1 inhibition on pulmonary eosinophilia after allergen challenge. METHODS: The Pin1 inhibitor juglone (5-hydroxy-1,4-naphthoquinone) was administered to allergen-sensitized and allergen-challenged Brown Norway rats. Bronchoalveolar lavage fluid and lungs were assessed for inflammation, cytokine expression, and Pin1 activity. RESULTS: Juglone-treated rats showed a dramatic reduction (approximately 75%) in bronchoalveolar lavage fluid and pulmonary eosinophilia but no change in lymphocyte, monocyte/macrophage, or neutrophil numbers. GM-CSF and IL-5 expression were also significantly reduced, whereas Pin1-independent cytokines, such as eotaxin or IL-4, as well as housekeeping mRNAs and proteins, including actin, were unaffected by juglone. The eosinophils present in the lung in juglone-treated rats showed significantly greater apoptosis. CONCLUSION: These data suggest that in vivo Pin1 blockade attenuates GM-CSF and IL-5 production and can selectively reduce eosinophilic allergic inflammation. CLINICAL IMPLICATIONS: Eosinophils can be selectively reduced by Pin1 blockade, despite allergen challenge.
BACKGROUND: Infiltration, accumulation, and degranulation of eosinophils in the lung are hallmarks of active allergic asthma. The pulmonary response to inhaled allergen triggers the secretion of eosinophil chemoattractants and antiapoptotic cytokines, including GM-CSF, IL-3, IL-4, IL-5, and eotaxin, among others. We recently showed that in vitro Pin1 regulated eosinophil production of and response to GM-CSF. OBJECTIVE: We sought to determine the effect of Pin1 inhibition on pulmonary eosinophilia after allergen challenge. METHODS: The Pin1 inhibitor juglone (5-hydroxy-1,4-naphthoquinone) was administered to allergen-sensitized and allergen-challenged Brown Norway rats. Bronchoalveolar lavage fluid and lungs were assessed for inflammation, cytokine expression, and Pin1 activity. RESULTS:Juglone-treated rats showed a dramatic reduction (approximately 75%) in bronchoalveolar lavage fluid and pulmonary eosinophilia but no change in lymphocyte, monocyte/macrophage, or neutrophil numbers. GM-CSF and IL-5 expression were also significantly reduced, whereas Pin1-independent cytokines, such as eotaxin or IL-4, as well as housekeeping mRNAs and proteins, including actin, were unaffected by juglone. The eosinophils present in the lung in juglone-treated rats showed significantly greater apoptosis. CONCLUSION: These data suggest that in vivo Pin1 blockade attenuates GM-CSF and IL-5 production and can selectively reduce eosinophilic allergic inflammation. CLINICAL IMPLICATIONS: Eosinophils can be selectively reduced by Pin1 blockade, despite allergen challenge.
Authors: Zhong-Jian Shen; Jie Hu; Venkatesh Kashi; Yury A Bochkov; James E Gern; James S Malter Journal: J Immunol Date: 2018-11-05 Impact factor: 5.422
Authors: Stephane Esnault; Louis A Rosenthal; Zhong-Jian Shen; Cara J Westmark; Ronald L Sorkness; James S Malter Journal: J Allergy Clin Immunol Date: 2008-04-18 Impact factor: 10.793
Authors: Zhong-Jian Shen; Jie Hu; Venkatesh P Kashi; Elizabeth A Kelly; Loren C Denlinger; Kevan Lutchman; Jeffrey G McDonald; Nizar N Jarjour; James S Malter Journal: Am J Respir Crit Care Med Date: 2017-06-15 Impact factor: 21.405
Authors: Zhong-Jian Shen; Stephane Esnault; Louis A Rosenthal; Renee J Szakaly; Ronald L Sorkness; Pamela R Westmark; Matyas Sandor; James S Malter Journal: J Clin Invest Date: 2008-02 Impact factor: 14.808
Authors: Zhong-Jian Shen; Stephane Esnault; Anna Schinzel; Christoph Borner; James S Malter Journal: Nat Immunol Date: 2009-02-01 Impact factor: 25.606